Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 4, 2026, 9:55 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1009–1032 of 9,992 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: TARGET Clear all

Conditions: Morbid Obesity, Surgery
Interventions: Rainbow sensor; Device
Lead sponsor: Masimo Corporation; Industry
Eligibility: 18 Years and older
Enrollment: 80 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2018
U.S. locations: 1
States / cities: Sacramento, California

Conditions: Hematologic Malignancies, Graft vs Host Disease
Interventions: reduced intensity, related donor stem cell transplant, tacrolimus (standard GVHD prophylaxis), mycophenolate (standard GVHD prophylaxis), vorinostat; Procedure · Drug
Lead sponsor: Pavan Reddy, MD; Other
Eligibility: 18 Years and older
Enrollment: 61 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2013
U.S. locations: 2
States / cities: Ann Arbor, Michigan • St Louis, Missouri

Conditions: Non Small Cell Lung Carcinoma
Interventions: Pemetrexed, Carboplatin; Drug
Lead sponsor: Instituto Nacional de Cancer, Brazil; Government
Eligibility: 18 Years and older
Enrollment: 228 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2012
U.S. locations: 1
States / cities: Miami Beach, Florida

Conditions: Hypertension
Interventions: L-citrulline; Dietary Supplement
Lead sponsor: Florida State University; Other
Eligibility: 18 Years to 35 Years · Male only
Enrollment: 16 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013 – 2014
U.S. locations: 1
States / cities: Tallahassee, Florida

Conditions: Head and Neck Cancer
Interventions: Pembrolizumab, Radiation; Drug · Radiation
Lead sponsor: Dana-Farber Cancer Institute; Other
Eligibility: 18 Years and older
Enrollment: 18 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2027
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Diabetes Mellitus, Type 1
Interventions: insulin, human insulin inhalation powder (HIIP); Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years and older
Enrollment: 119 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2004
U.S. locations: 25
States / cities: San Diego, California • Denver, Colorado • Hollywood, Florida + 22 more

Conditions: Overweight in Preschool Age Children, Risk of Overweight in Preschool Age Children
Interventions: To change structure and roles of primary care teams to optimize prevention of obesity; Behavioral
Lead sponsor: Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD); NIH
Eligibility: 2 Years to 6 Years
Enrollment: 500 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2009
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Carotid Artery Diseases, Atherosclerosis
Interventions: Valsartan, Placebo; Drug
Lead sponsor: Emory University; Other
Eligibility: 21 Years to 80 Years
Enrollment: 120 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2009
U.S. locations: 1
States / cities: Atlanta, Georgia

Conditions: Herpes Simplex
Interventions: Non-adjuvanted HSV formulation 1, Non-adjuvanted HSV formulation 2, Non-adjuvanted HSV formulation 3, HSV formulation 1 with adjuvant 1, HSV formulation 2 with adjuvant 1, HSV formulation 3 with adjuvant 1, HSV formulation 1 with adjuvant 2, HSV formulation 2 with adjuvant 2, HSV formulation 3 with adjuvant 2, Placebo, HSVTI_F1, HSVTI_F2; Biological · Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years to 60 Years
Enrollment: 505 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2025
U.S. locations: 6
States / cities: Phoenix, Arizona • Wichita, Kansas • Kansas City, Missouri + 3 more

Conditions: Acute Myeloid Leukemia
Interventions: Azacitidine and Venetoclax; Drug
Lead sponsor: University of Colorado, Denver; Other
Eligibility: 60 Years and older
Enrollment: 42 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2025
U.S. locations: 1
States / cities: Aurora, Colorado

Conditions: Cardiac Events, Emotions
Interventions: eMotion; Behavioral
Lead sponsor: Indiana University; Other
Eligibility: 18 Years and older
Enrollment: 5 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024
U.S. locations: 1
States / cities: Indianapolis, Indiana

Conditions: Neoplasms
Interventions: BAY1000394; Drug
Lead sponsor: Bayer; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2011
U.S. locations: 3
States / cities: Scottsdale, Arizona • St Louis, Missouri • Chapel Hill, North Carolina

Conditions: Breast Cancer
Interventions: vepdegestrant, Samuraciclib; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years and older
Enrollment: 11 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2026
U.S. locations: 19
States / cities: Fayetteville, Arkansas • Rogers, Arkansas • Springdale, Arkansas + 9 more

Conditions: Blood Loss, Surgical, Postoperative Hemorrhage
Interventions: Wearable optical hemodynamic monitoring device; Device
Lead sponsor: Hemorai Inc; Industry
Eligibility: Not listed
Enrollment: 80 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: Burlington, Massachusetts

Conditions: Solid Tumor, Gastric Cancer, Gastroesophageal Junction Adenocarcinoma, Esophageal Adenocarcinoma, Pancreatic Cancer, Biliary Tract Cancer, Cholangiocarcinoma, Metastatic Cancer
Interventions: BNT141, Nab-paclitaxel, Gemcitabine; Drug
Lead sponsor: BioNTech SE; Industry
Eligibility: 18 Years and older
Enrollment: 13 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2023
U.S. locations: 4
States / cities: Duarte, California • Houston, Texas • San Antonio, Texas

Conditions: Sensory Nerve Conduction, Oxyneurogram Index
Interventions: tourniquet, sensory nerve conduction abnormality; Device
Lead sponsor: Duke University; Other
Eligibility: 18 Years to 75 Years
Enrollment: 10 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014 – 2016
U.S. locations: 1
States / cities: Durham, North Carolina

Conditions: Lupus Nephritis
Interventions: Obinutuzumab, Placebo, Mycophenolate Mofetil, Acetaminophen/paracetamol, Diphenhydramine hydrochloride (HCl), Methylprednisolone, Prednisone; Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 5 Years to 17 Years
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2030
U.S. locations: 11
States / cities: Loma Linda, California • San Francisco, California • Aurora, Colorado + 8 more

Conditions: Excess Abdominal Fat
Interventions: UltraShape Power; Device
Lead sponsor: Syneron Medical; Industry
Eligibility: 18 Years to 60 Years
Enrollment: 62 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016 – 2018
U.S. locations: 8
States / cities: Sacramento, California • Jacksonville Beach, Florida • Miami, Florida + 5 more

Conditions: Obesity, Physical Activity
Interventions: PPPA, PA; Behavioral
Lead sponsor: Brown University; Other
Eligibility: 18 Years and older
Enrollment: 54 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2020
U.S. locations: 1
States / cities: Providence, Rhode Island

Conditions: Advanced Cancers
Interventions: Temsirolimus; Drug
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: Not listed
Enrollment: 44 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2014
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Sepsis
Interventions: personalized dosing adjustment of vancomycin; Other
Lead sponsor: Children's Hospital of Philadelphia; Other
Eligibility: 1 Month to 17 Years
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Stroke
Interventions: Telerehabilitation; Device
Lead sponsor: University of California, Los Angeles; Other
Eligibility: 18 Years to 85 Years
Enrollment: 202 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2030
U.S. locations: 27
States / cities: Downey, California • Irvine, California • Los Angeles, California + 20 more

Conditions: Asthma
Interventions: AIM2ACT, mHealth Attention Control Condition; Behavioral
Lead sponsor: University of Florida; Other
Eligibility: 12 Years to 70 Years
Enrollment: 320 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2026
U.S. locations: 2
States / cities: Gainesville, Florida • Jacksonville, Florida

Conditions: Gout
Interventions: Allopurinol, Naproxen 250 MG, Colchicine 0.6 mg, Colchicine 1.2 mg, Naproxen 500 Mg, Prednisone 40 mg; Drug
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 18 Years to 90 Years
Enrollment: 650 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2028
U.S. locations: 7
States / cities: South Birmingham, Alabama • Santa Monica, California • Boston, Massachusetts + 2 more

Search by objective public record fields.

Oxygen Reserve Index: Utility as Early Warning for Desaturation in Morbidly Obese Patients

Vorinostat to Prevent Graft Versus Host Disease Following Reduced Intensity, Related Donor Stem Cell Transplant

Alimta® Versus Its Combination With Carboplatin in Advanced Non-small-cell Lung Cancer in Patients Performance Status 2

L-citrulline Supplementation, Cold Exposure, & Post-Exercise Muscle Ischemia

Targeting PD-1 Therapy Resistance With Focused High or High and Low Dose Radiation in SCCHN

Safety and Efficacy of Human Insulin Inhalation Powder in Patients With Type 1 Diabetes Mellitus.

Improving Primary Care to Prevent Childhood Obesity

Effect of Valsartan on Carotid Artery Disease

A Study on the Reactogenicity, Safety, Immune Response, and Efficacy of a Targeted Immunotherapy Against HSV in Healthy Participants Aged 18-40 Years or in Participants Aged 18-60 Years With Recurrent Genital Herpes

Azacitidine and Venetoclax as Induction Therapy With Venetoclax Maintenance in the Elderly With AML

Satisfaction With eMotion in a Diverse Group of Women

Clinical Study to Evaluate Safety and Maximum Tolerated Dose of BAY1000394 Given in a 4 Week on / 2 Week Off Schedule in Subjects With Advanced Malignancies

TACTIVE-U: A Study to Learn About the Study Medicine (Vepdegestrant) When Given With Other Medicines in People With Advanced or Metastatic Breast Cancer. (Sub-Study C)

Study of the Hemorai Vysio Wearable Device for Monitoring Changes Related to Blood Loss in Patients During and After Surgery.

Safety, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy Trial of BNT141 in Patients With Unresectable or Metastatic CLDN18.2-positive Gastric, Pancreatic, Ovarian and Biliary Tract Tumors

Effect of Tourniquet on Sensory Nerve Conduction Threshold (sNCT) and OxyNeuroGram (ONG) Index- A Volunteer Study

A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Obinutuzumab in Adolescents With Active Class III or IV Lupus Nephritis and the Safety and PK of Obinutuzumab in Pediatric Participants

UltraShape Power for Abdominal Fat and Circumference Reduction

Positive Psychology for Physical Activity Promotion

Phosphatidylinositol 3 Kinase and Mammalian Target of Rapamycin (PI3K-mTOR) in Advanced Cancer Patients

Vancomycin and Acute Kidney Injury in Sepsis Treatment - Intervention

Telerehabilitation In The Home After Stroke

AIM2ACT: A Mobile Health Tool to Help Adolescents Self-Manage Asthma

Treat-to-Target Serum Urate Versus Treat-to-Avoid Symptoms in Gout